U.S. Treatment-resistant Depression Treatment Market Size, Share & COVID-19 Impact Analysis, By Drug Type (N-Methyl-D-aspartate (NMDA)), Antidepressants, Antipsychotics, and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Country Forecast, 2023-2030

The U.S. treatment-resistant depression treatment market size was worth USD 873.2 million in 2022 and is projected to grow at a CAGR of 9.2% during the forecast period.

The U.S. has observed a high prevalence of depression, which has increased the number of patients seeking treatment-resistant depression treatment. The growing patient population and high demand for this treatment have increased the market players' focus on preventing the disease. Furthermore, an increase in the introduction of novel drugs is expected to boost market growth in the coming years.

• According to a study by the Journal of Clinical Psychiatry published in March 2021, the prevalence of medication-treated major depression disorders among the U.S. population was 8.9 million, of which 2.8 million or 30.9% of adults had treatment-resistant depression. The total annual cost of treating the condition was around USD 92.7 million, out of which around 47.2% or USD 43.8 million is allocated to treatment-resistant depression.

The growing adoption of this treatment among the patient population, coupled with the awareness campaigns initiated for this treatment, is expected to propel market growth.

In 2020, during the pandemic, the market experienced positive growth in the U.S. This growth was attributed to the increased R&D activities and high demand for therapeutic measures to treat mental health disorders across the country.

LATEST TRENDS

Growing Focus on Developing Novel Routes of Administration for Treatment-resistant Depression Treatment

In recent years, market players have increased their focus on the development of new routes of administration of the drugs used in the treatment. Currently, they are developing drugs that can be administered through the nasal and intravenous routes rather than the traditional oral route.

The clinical benefits of other routes over the oral route of administration, such as effective results within hours of administration, lesser risks, and better outcomes, are responsible for higher preference toward alternate routes.

• For instance, in March 2019, Janssen Pharmaceuticals, Inc. developed Spravato (esketamine), a nasal spray, in conjunction with an oral antidepressant that received U.S. FDA approval for treating adult patients with TRD.

DRIVING FACTORS

Surge in Drug Development Projects for TRD to Boost Market Growth

The market players have increased their focus on drug development for this disease in the U.S. Various pharmaceutical and Life science companies are vigorously funding experimental studies of possible pipeline entrants to launch innovative products for TRD treatment.

• In February 2022, Denova Biopharma secured the U.S. FDA approval to initiate a Phase 2b clinical trial to analyze the safety and efficacy of DB104 (liafensine) in patients with treatment-resistant depression.

The growing focus of market players on developing innovative drugs, coupled with the rising prevalence of depression, is anticipated to boost the demand for these drugs. This factor will propel the U.S. treatment-resistant depression treatment market growth in the coming years.

In the U.S., the prevalence of treatment-resistant depression was 2,788,946 in 2022, whereas it was 2,776,056 in 2021.

RESTRAINING FACTORS

Poor Management of Treatment-resistant Depression to Hinder Market Growth

Despite the increasing focus of market players on investing in the research and development of innovative drug therapies for the treatment of TRD, the poor management of mood disorders is hindering the growth of the market.

One of the most significant challenges in the treatment of this form of depression is The absence of clear diagnosis in patients. Often, patients discontinue treatment as they see little to no improvement in their condition, which limits the adoption of the drugs for treatment-resistant depression treatment.

• For instance, as per a research report published by the NIH in December 2020, 41% of doctors reported that treatment interruption and loss of follow-up are the main issues in the management of the disease.

Additionally, factors such as the social and cultural stigma of reporting non-response to treatment and poor patient management are also expected to limit the market growth during the forecast period.

SEGMENTATION

By Drug Type Analysis

Based on drug type, the market is segmented into N-methyl-D-aspartate (NMDA), antidepressants, antipsychotics, and others.

The N-Methyl-D-aspartate (NMDA) segment is anticipated to record the highest CAGR during the forecast period. The segment's growth is due to the rising prevalence of treatment-resistant depression, coupled with the increase in patient visits to hospitals. Furthermore, the increased focus of market players on the research and development of NMDA is expected to contribute to the segment’s growth.

By Distribution Channel Analysis

Based on distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.

The hospital pharmacies segment held a larger market share in 2022 and is expected to record the highest CAGR during the forecast period. The segment’s highest share is attributed to the presence of a large patient population seeking treatment-resistant depression treatment in hospitals, thereby increasing the demand for these drugs in hospital pharmacies.

KEY INDUSTRY PLAYERS

In terms of the competitive landscape, Eli Lilly and Company, Pfizer Inc., and GlaxoSmithKline plc are leading players in the market. Eli Lilly and Company is dominating the U.S. treatment-resistant depression treatment market share due to its strong and direct presence and broad range of antipsychotics and antidepressants for treatment.

Some other companies with a considerable presence in the U.S. market include Janssen Global Services, LLC, AbbVie Inc., Sandoz International GmbH (Novartis AG), H. Lundbeck A/S, AstraZeneca and others, as well as other small & medium-sized players. These companies are entering strategic collaborations and acquisitions with other market players to increase their presence in this market.

LIST OF KEY COMPANIES PROFILED:

• Eli Lilly and Company (U.S.)


• GlaxoSmithKline (U.K.)


• Pfizer Inc. (U.S.)


• Janssen Global Services, LLC (Johnson & Johnson Services, Inc.) (Belgium)


• AbbVie Inc. (U.S.)


• AstraZeneca (U.K.)


• H. Lundbeck A/S (Denmark)


• Sandoz International GmbH (Novartis AG) (Germany)

KEY INDUSTRY DEVELOPMENTS:

• January 2023 - GH Research received approvals for the Phase IIb trial of GH001 in TRD (GH001-TRD-201), and the company is expected to initiate the clinical trial in Q1- 2023.


• September 2021 - Perception Neuroscience announced the initiation of the Phase IIa clinical trial to investigate the efficacy and safety of PCN-101 (R-ketamine) for treatment-resistant depression disorder treatment.


• January 2022 - Atai Life Sciences announced that it had received the FDA Investigational New Drug (IND) Clearance for its PCN-101 R-ketamine Program for treatment-resistant depression treatment.

REPORT COVERAGE

The market research report provides a detailed analysis of the market. It focuses on key aspects, such as the regulatory scenarios, the prevalence of TRD, and an overview of current advancements in R&D for launching novel drugs in the market. Additionally, it includes an overview of the market segments, key industry developments, and the impact of COVID-19 on the market.

Report Scope & Segmentation